AH13205
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 531429

CAS#: 148436-63-9

Description: AH13205 is an EP2 prostanoid receptor agonist.


Chemical Structure

img
AH13205
CAS# 148436-63-9

Theoretical Analysis

MedKoo Cat#: 531429
Name: AH13205
CAS#: 148436-63-9
Chemical Formula: C24H36O4
Exact Mass: 388.26
Molecular Weight: 388.548
Elemental Analysis: Chemical Formula: C24H36O4 Exact Mass: 388.2614 Molecular Weight: 388.5480 Elemental Analysis: C, 74.19; H, 9.34; O, 16.47

Price and Availability

Size Price Availability Quantity
1mg USD 350
5mg USD 1100
Bulk inquiry

Synonym: AH13205, AH 13205, AH-13205

IUPAC/Chemical Name: 7-[2-[4-(1-hydroxyhexyl)phenyl]-5-oxocyclopentyl]heptanoic acid

InChi Key: XMQKDOCUWFCMEJ-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H36O4/c1-2-3-6-10-22(25)19-14-12-18(13-15-19)20-16-17-23(26)21(20)9-7-4-5-8-11-24(27)28/h12-15,20-22,25H,2-11,16-17H2,1H3,(H,27,28)

SMILES Code: O=C(O)CCCCCCC1C(C2=CC=C(C(O)CCCCC)C=C2)CCC1=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 388.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Dennis S, Hasan I, Pulver LJ, Wilson I, Zwar N. Experiences and views of a brokerage model for primary care for Aboriginal people. Aust Health Rev. 2015 Feb;39(1):26-32. PubMed PMID: 25318845.

2: Kay LJ, Gilbert M, Pullen N, Skerratt S, Farrington J, Seward EP, Peachell PT. Characterization of the EP receptor subtype that mediates the inhibitory effects of prostaglandin E2 on IgE-dependent secretion from human lung mast cells. Clin Exp Allergy. 2013 Jul;43(7):741-51. doi: 10.1111/cea.12142. PubMed PMID: 23786281.

3: Buckley J, Birrell MA, Maher SA, Nials AT, Clarke DL, Belvisi MG. EP4 receptor as a new target for bronchodilator therapy. Thorax. 2011 Dec;66(12):1029-35. doi: 10.1136/thx.2010.158568. PubMed PMID: 21606476; PubMed Central PMCID: PMC3221321.

4: Bate C, Tayebi M, Williams A. Phospholipase A2 inhibitors protect against prion and Abeta mediated synapse degeneration. Mol Neurodegener. 2010 Apr 8;5:13. doi: 10.1186/1750-1326-5-13. PubMed PMID: 20374666; PubMed Central PMCID: PMC2865460.

5: Ohmiya H, Yorimitsu H, Oshima K. Cobalt(diamine)-catalyzed cross-coupling reaction of alkyl halides with arylmagnesium reagents: stereoselective constructions of arylated asymmetric carbons and application to total synthesis of AH13205. J Am Chem Soc. 2006 Feb 15;128(6):1886-9. PubMed PMID: 16464089.

6: Stumpff F, Boxberger M, Krauss A, Rosenthal R, Meissner S, Choritz L, Wiederholt M, Thieme H. Stimulation of cannabinoid (CB1) and prostanoid (EP2) receptors opens BKCa channels and relaxes ocular trabecular meshwork. Exp Eye Res. 2005 May;80(5):697-708. PubMed PMID: 15862177.

7: Kobayashi Y, Nakata K, Ainai T. New reagent system for attaining high regio- and stereoselectivities in allylic displacement of 4-cyclopentene-1,3-diol monoacetate with aryl- and alkenylmagnesium bromides. Org Lett. 2005 Jan 20;7(2):183-6. PubMed PMID: 15646953.

8: Richter M, Krauss AH, Woodward DF, Lütjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4419-26. PubMed PMID: 14507888.

9: Guan Y, Stillman BA, Zhang Y, Schneider A, Saito O, Davis LS, Redha R, Breyer RM, Breyer MD. Cloning and expression of the rabbit prostaglandin EP2 receptor. BMC Pharmacol. 2002 Jun 27;2:14. PubMed PMID: 12097143; PubMed Central PMCID: PMC117438.

10: Hu DN, McCormick SA, Woodward DF. A functional study on prostanoid receptors involved in cultured human iridal melanocyte stimulation. Exp Eye Res. 2001 Jul;73(1):93-100. PubMed PMID: 11428866.

11: Hillock CJ, Crankshaw DJ. Inhibitory prostanoid EP receptors in human non-pregnant myometrium. Eur J Pharmacol. 1999 Jul 28;378(1):99-108. PubMed PMID: 10478569.

12: Madhu C, Rix P, Nguyen T, Chien DS, Woodward DF, Tang-Liu DD. Penetration of natural prostaglandins and their ester prodrugs and analogs across human ocular tissues in vitro. J Ocul Pharmacol Ther. 1998 Oct;14(5):389-99. PubMed PMID: 9811228.

13: Spicuzza L, Giembycz MA, Barnes PJ, Belvisi MG. Prostaglandin E2 suppression of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by interacting with prostanoid receptors of the EP3-subtype. Br J Pharmacol. 1998 Mar;123(6):1246-52. PubMed PMID: 9559911; PubMed Central PMCID: PMC1565272.

14: Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. PubMed PMID: 9313928; PubMed Central PMCID: PMC1564924.

15: Meja KK, Barnes PJ, Giembycz MA. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation. Br J Pharmacol. 1997 Sep;122(1):149-57. PubMed PMID: 9298541; PubMed Central PMCID: PMC1564914.

16: Teixeira MM, al-Rashed S, Rossi AG, Hellewell PG. Characterization of the prostanoid receptors mediating inhibition of PAF-induced aggregation of guinea-pig eosinophils. Br J Pharmacol. 1997 May;121(1):77-82. PubMed PMID: 9146890; PubMed Central PMCID: PMC1564656.

17: Krauss AH, Wiederholt M, Sturm A, Woodward DF. Prostaglandin effects on the contractility of bovine trabecular meshwork and ciliary muscle. Exp Eye Res. 1997 Mar;64(3):447-53. PubMed PMID: 9196397.

18: Lydford SJ, McKechnie KC, Dougall IG. Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: a comparison with the rabbit isolated ear artery. Br J Pharmacol. 1996 Jan;117(1):13-20. PubMed PMID: 8825337; PubMed Central PMCID: PMC1909359.

19: Armstrong RA. Investigation of the inhibitory effects of PGE2 and selective EP agonists on chemotaxis of human neutrophils. Br J Pharmacol. 1995 Dec;116(7):2903-8. PubMed PMID: 8680723; PubMed Central PMCID: PMC1909222.

20: De Vries GW, Guarino P, McLaughlin A, Chen J, Andrews S, Woodward DF. An EP receptor with a novel pharmacological profile in the T-cell line Jurkat. Br J Pharmacol. 1995 Aug;115(7):1231-4. PubMed PMID: 7582550; PubMed Central PMCID: PMC1908800.